Zontivity Wins FDA Approval to Prevent Heart Attacks

(MedPage Today) -- The tortuous road to market for novel antiplatelet vorapaxar (Zontivity) has come to an end: the FDA approved the drug for prevention of myocardial infarction, stroke, and cardiovascular death in high-risk patients. via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/QjXpQe